Table 1.

Clinical information and genotype of the Adelaide cohort

Patient ID	Age at operation	Gender	Diagnosis	Histopathology	Germline ARMC5 mutation status
III-1	69	M	Cushing's due to PBMAH	PBMAH	Chr16:g.31476121; c.1777C→T; p.(R593W)
III-2	62	M	Cushing's due to PBMAH	PBMAH	Chr16:g.31476121; c.1777C→T; p.(R593W)
III-3	66	M	Cushing's due to PBMAH	PBMAH	Chr16:g.31476121; c.1777C→T; p.(R593W)
CS-01	39	F	Cushing's syndrome	Adrenal adenoma	not tested
CS-02	48	F	Cushing's syndrome	Adrenal adenoma	not tested
PA-01	57	M	Primary aldosteronism	Adrenal adenoma	not tested
PA-02	76	M	Primary aldosteronism	Adrenal hyperplasia - micro- and macronodular	not tested
PA-03	50	M	Primary aldosteronism	Adrenal hyperplasia - micro- and macronodular	not tested
N-1	50	M	normal adrenal gland a	N/A	not tested
N-2	unknown	M	normal adrenal gland b	N/A	not tested

For RPB1 expression analysis, PBMAH macronodules were obtained from resected adrenal glands of PBMAH patients with germline ARMC5 mutations. Adrenal gland adenomas and adrenocortical carcinoma tissues not known to have ARMC5 mutations were used as controls. The clinical diagnosis and histopathology of the patients are indicated. ^aThe normal adrenal gland of patient N-1 was obtained from normal tissues adjacent to the adrenal gland adenoma of patient PA-03. ^bNormal adrenal gland N-2 was obtained from a patient undergoing nephrectomy for renal cell carcinoma. PBMAH: primary bilateral macronodular adrenal gland hyperplasia. N/A: not applicable.